Dan Ou1, Pierre Blanchard2, Silvia Rosellini3, Antonin Levy2, France Nguyen2, Ralph T H Leijenaar4, Ingrid Garberis5, Philippe Gorphe6, François Bidault7, Charles Ferté6, Charlotte Robert2, Odile Casiraghi5, Jean-Yves Scoazec5, Philippe Lambin4, Stephane Temam6, Eric Deutsch2, Yungan Tao8. 1. Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France. 3. Department of Biostatistics, Institut Gustave Roussy, Villejuif, France. 4. Department of Radiation Oncology, MAASTRO Clinic, Research Institute GROW, Maastricht University, 6229ET Maastricht, The Netherlands. 5. Department of Pathology, Institut Gustave Roussy, Villejuif, France. 6. Department of Head and Neck Oncology, Institut Gustave Roussy, Villejuif, France. 7. Department of Radiology, Institut Gustave Roussy, Villejuif, France. 8. Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France. Electronic address: yungan.tao@gustaveroussy.fr.
Abstract
OBJECTIVES: To explore prognostic and predictive value of radiomics in patients with locally advanced head and neck squamous cell carcinomas (LAHNSCC) treated with concurrent chemoradiotherapy (CRT) or bioradiotherapy (BRT). MATERIALS AND METHODS: Data of 120 patients (CRT vs. BRT matched 2:1) were retrospectively analyzed. A total of 544 radiomics features of the primary tumor were extracted from radiotherapy planning computed tomography scans. Cox proportional hazards models were used to examine the association between survival and radiomics features with false discovery rate correction. The discriminatory performance was evaluated using receiver operating characteristic curve analysis. RESULTS: Multivariate analysis showed a 24-feature based signature significantly predicted for OS (HR=0.3, P=0.02) and progression-free survival (PFS) (HR=0.3, P=0.01). Combining the radiomics signature with p16 status showed a significant improvement of prognostic performance compared with p16 (AUC=0.78vs. AUC=0.64 at 5years, P=0.01) or radiomics signature (AUC=0.78vs. AUC=0.67, P=0.01) alone. When patients were stratified according to this combination, OS and PFS were significantly different according to the 4 sub-types (p16+ with low/high signature score; p16- with low/high signature score) (P<0.001). Patients with high signature score significantly benefited from CRT (vs. BRT) in terms of OS (P=0.004), while no benefit from CRT in patients with low signature score. CONCLUSION: Our analysis suggests an added value of radiomics features as prognostic and predictive biomarker in HNSCC treated with CRT/BRT. Moreover, the radiomics signature provided additional information to HPV/p16 status to further stratify patients. External validation of such findings is mandatory given the risk of overfitting.
OBJECTIVES: To explore prognostic and predictive value of radiomics in patients with locally advanced head and neck squamous cell carcinomas (LAHNSCC) treated with concurrent chemoradiotherapy (CRT) or bioradiotherapy (BRT). MATERIALS AND METHODS: Data of 120 patients (CRT vs. BRT matched 2:1) were retrospectively analyzed. A total of 544 radiomics features of the primary tumor were extracted from radiotherapy planning computed tomography scans. Cox proportional hazards models were used to examine the association between survival and radiomics features with false discovery rate correction. The discriminatory performance was evaluated using receiver operating characteristic curve analysis. RESULTS: Multivariate analysis showed a 24-feature based signature significantly predicted for OS (HR=0.3, P=0.02) and progression-free survival (PFS) (HR=0.3, P=0.01). Combining the radiomics signature with p16 status showed a significant improvement of prognostic performance compared with p16 (AUC=0.78vs. AUC=0.64 at 5years, P=0.01) or radiomics signature (AUC=0.78vs. AUC=0.67, P=0.01) alone. When patients were stratified according to this combination, OS and PFS were significantly different according to the 4 sub-types (p16+ with low/high signature score; p16- with low/high signature score) (P<0.001). Patients with high signature score significantly benefited from CRT (vs. BRT) in terms of OS (P=0.004), while no benefit from CRT in patients with low signature score. CONCLUSION: Our analysis suggests an added value of radiomics features as prognostic and predictive biomarker in HNSCC treated with CRT/BRT. Moreover, the radiomics signature provided additional information to HPV/p16 status to further stratify patients. External validation of such findings is mandatory given the risk of overfitting.
Authors: Rachel B Ger; Daniel F Craft; Dennis S Mackin; Shouhao Zhou; Rick R Layman; A Kyle Jones; Hesham Elhalawani; Clifton D Fuller; Rebecca M Howell; Heng Li; R Jason Stafford; Laurence E Court Journal: Comput Med Imaging Graph Date: 2018-09-15 Impact factor: 4.790
Authors: William Rogers; Sithin Thulasi Seetha; Turkey A G Refaee; Relinde I Y Lieverse; Renée W Y Granzier; Abdalla Ibrahim; Simon A Keek; Sebastian Sanduleanu; Sergey P Primakov; Manon P L Beuque; Damiënne Marcus; Alexander M A van der Wiel; Fadila Zerka; Cary J G Oberije; Janita E van Timmeren; Henry C Woodruff; Philippe Lambin Journal: Br J Radiol Date: 2020-02-26 Impact factor: 3.039